FDA OKs Subcutaneous Mosunetuzumab for Follicular LymphomaJanuary 6, 2026Lymphoma & Plasma Cell DisordersFDA Actions
Do Erythropoiesis-Stimulating Agents Have a Risk Evaluation and Mitigation Strategy? (FULL)August 2, 2018HematologyFDA Actions
.jpg)